New immunotherapy cocktails aim to tackle Hard-to-Treat breast cancer
NCT ID NCT03280563
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested several immunotherapy-based drug combinations in 144 people with advanced hormone receptor-positive, HER2-negative breast cancer that had worsened after initial treatment. Participants received atezolizumab (Tecentriq) along with other drugs like bevacizumab or fulvestrant. The goal was to see if these combinations could shrink tumors or slow disease progression. The trial is now complete, and results will help guide future treatment options.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Atezolizumab (Tecentriq) plus other drugs like bevacizumab or fulvestrant
- What this could lead to
- If successful, this could provide new treatment options for people with advanced breast cancer that has stopped responding to standard therapies.
- What could go wrong
- This is an early-phase study with a small number of participants, so results may not apply to everyone. Immunotherapy can cause immune-related side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21231, United States
-
Levine Cancer Institute
Charlotte, North Carolina, 28204, United States
-
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Torrance, California, 90502, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
National Cancer Center
Gyeonggi-do, 10408, South Korea
-
Northwest Georgia Oncology Centers PC - Marietta
Marietta, Georgia, 30060, United States
-
Providence Cancer Center
Portland, Oregon, 97231, United States
-
Rabin Medical Center-Beilinson Campus
Petah Tikva, 4941492, Israel
-
Rambam Medical Center
Haifa, 3109601, Israel
-
Sarah Cannon Research Institute / Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
Shaare Zedek Medical Center
Jerusalem, 9103102, Israel
-
Sheba Medical Center
Ramat Gan, 5262100, Israel
-
Stanford Cancer Institute
Stanford, California, 94305-5456, United States
-
Tel Aviv Sourasky Medical Center
Tel Aviv, 64239, Israel
-
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania, 19107, United States
-
UCSF Helen Diller Family CCC
San Francisco, California, 94158, United States
-
UPMC Pinnacle Health System
Harrisburg, Pennsylvania, 17102, United States
-
Univ of Pittsburgh Sch of Med
Pittsburgh, Pennsylvania, 15213, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35249, United States
-
University of Ulsan College of Medicine - Asan Medical Center
Seoul, 05505, South Korea
-
Wellness Oncology and Hematology - Main Office
West Hills, California, 91307, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Smartwatch could spot nerve damage before it starts
- Can acupuncture soothe the mind and body in breast cancer?
- CT scans may predict breast reconstruction flap failure
- A gentle jog might be the key to better sleep for breast cancer survivors
- Peer power: could community education boost cancer screening?
- Robotic vs. endoscopic: which biopsy method is more accurate for breast cancer?